North America is the key growthengine in the global hemostasis diagnostics market
Regional segmentation of the HemostasisDiagnostic Market by Coherent Market Insights comprises North America,Europe, Asia Pacific, Latin America, Middle East, and Africa. According to theCentre for Disease Control and Prevention in 2015, the number of people withhemophilia in the U.S. is estimated to be 20,000.
This positions North America asthe most dominant region in the global hemostasis diagnostics market, owing tothe rise in installed instruments leading to higher sales of reagents andsupport services. According to The European National Registry of CongenitalCoagulopathies in 2017, the number of people identified with hemostasis hasincreased from 7000 in 2000 to over 11,000 in 2015.
Therefore, the European market isexpected to grow steadily boosting the demand for hemostasis diagnostics.Significant growth of markets in India, China, and Brazil is registering due tothe rise in health care expenditure, higher affordability, improving technicalcapabilities and economic development. These markets are expected to attractglobal companies for capitalizing on the hemostasis diagnostics marketopportunities.
Hemostasis diagnostics helpidentify the hemostatic defects that cause excessive bleeding. Hemostasis is aprocess of slowing and stopping the blood flow to initiate wound healing aftera vascular injury and is the key procedure acting in the first line of actionadopted by the body. During the process, blood changes its form from the fluidstate to the gelatinous state. Hemostasis is maintained in the body via threemechanisms namely vasoconstriction, platelet plug formation, and bloodcoagulation.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/434
The diagnosis helps predict thecause of excessive bleeding during the surgery, identifies hemostatic defectsin patients with a history of excessive bleeding. Based on the researcharticles published by medical experts, the appropriate therapy to treathemorrhage can be administered of fresh frozen plasma for coagulation defects,Von Willebrand factor concentrates for platelet function defects orantifibrinolytic agents for systemic fibrinolysis.
Rising prevalence of hemophiliadrives the hemostasis diagnostics market globally
The critical nature of theprocedure in the field of medicine and healthcare has gained a prominentposition in the hemostasis diagnostics market. According to the NationalHemophilia Foundation in 2012, the global incidence of hemophilia is estimatedto be 400,000 people. The rise in the prevalence of genetically inheriteddisorders such as hemophilia, an increase in the number of surgeries and traumapatients, the surge in the usage of recombinant products are the collectivefactors driving the global market.
The growing technologicaladvances in molecular diagnostics, inexpensive and biodegradable diagnosticproducts, chromogenic substrates, monoclonal antibodies, immunoassays,laboratory automation is estimated to radically change the Hemostasis diagnosticsmarket over the following five years.
U.S. Beckman Coulter holds overhalf the U.S. market for Hematology devices
Key players operating in themarket are HORIBA, Ltd., Abbott Laboratories, Siemens AG, and Bio-RadLaboratories, Inc. The high and low-end analyzers provided by U.S. BeckmanCoulter meet the needs of all hematology testing environment. Other vendors whohave adopted ideal product models, business expansion and market appealstrategies are Becton, Dickinson & Company, Grifols S.A, Alere, Inc., F.Hoffmann-La Roche AG, Beckman Coulter Inc. Sekisui, Helena Labor, Chrono-Log,and Axis-Shield.
Browse ResearchReport: https://www.coherentmarketinsights.com/ongoing-insight/hemostasis-diagnostics-market-434
Key Development
In February 2019, Horiba Medical,launched their new parameter, Yumizen D-Dimer, for its Yumizen G Hemostasisrange of instruments to diagnose deep vein thrombosis and pulmonary embolism.
In 2017, Werfen and it'ssubsidiary Instrumentation Laboratory Company acquired Accriva Diagnostics, toexpand leadership in point of care testing.
In 2016, Siemens Healthineerslaunched Sysmex CS-2500 a new mid-volume coagulation analyzer. Which enablelabs to provide quality test results and achieve cost-effective methodconsolidation.
In 2015, Roche AG launched thenew lab-coagulation solution, the cobas t 411 analyzer is lab coagulationsystem suitable for low volume routine testing (up to 120 samples per day),with this launch Roche AG expanded their diagnostic portfolio.
In 2014, Sysmex Corporation,launched LIASAUTO P-FDP hemostasis reagent for automated coagulation analyzersto determine the status of blood hyperfibrinolysis and hypercoagulable
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/434
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
